BioSpace News Archive

Ozop Surgical Corp. ( OZSC ), (“Ozop” or the “Company”), is pleased to announce that it has completed its acquisition of Power Conversion Technologies, Inc. (PCTI), a 29-year-old manufacturer of high power solutions for energy storage, defense, maritime power, and other industries. Ozop will adopt its new name, Ozop Energy Solutions, to reflect the new strategy resul

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates, today announced that the company has been added to the Russell 3000 ® index, effective after the U.S. market opens today, following R

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization for smoking cessation

Achieve Life Sciences, Inc. (Nasdaq: ACHV), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 14,634,146 shares of common stock at a price of $0.41

Bladder EpiCheck® demonstrated superior performance to cytology alone with high sensitivity, specificity and NPV in a high-risk non-muscle invasive bladder cancer population undergoing instillations Study conducted at Agostino Gemelli University Hospital in Rome, Italy, shows it would be safe and effective to use Bladder EpiCheck to avoid unnecessary cystoscopies in high-risk patients SAN DIEGO & REHOVOT, Israel--( BUSINESS WIRE )-- Nucle

Medable Inc., the leading software provider for decentralized clinical trials, and Datavant, the leader in helping healthcare organizations safely connect their data, today announced a partnership that will help clinical trial teams easily integrate multiple data sources to accelerate decentralized trial design, recruitment and data management.

Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com.

Recent $4.2 Million NCI Grant for FABP5 Inhibitor Development Demonstrates Validation of the Platform

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm® mass cytometry technology and the Maxpar® Direct™ Immune Profiling Assay™ are being utilized in a prospective observational cohort surveillance study of up to 2,000 adult participants hospitalized with COVID-19.

DURECT Corporation announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens, June 29, 2020.